Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium Expands Drug Discovery Collaboration with Elan

NEW YORK, Oct. 6 (GenomeWeb News) - Ingenium Pharmaceuticals said today that it has expanded its drug discovery partnership with Elan to include areas outside pain management.


In March, the companies inked a deal under which Ingenium uses its functional genomics tools to identify and clone for Elan molecular targets involved in the molecular mechanisms involved in the control of pain.


According to Ingenium, it has been producing genetically altered mouse models for Elan's use in pain management drug target validation.  With the expansion of the deal, it will produce additional models to be used in other areas of research.


Specific terms of the deal were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.